Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
General Thoracic and Cardiovascular Surgery
Published in: General Thoracic and Cardiovascular Surgery 7/2016

01-07-2016 | Current Topics Review Article

Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management

Authors: Masahiko Ikebe, Masaru Morita, Manabu Yamamoto, Yasushi Toh

Published in: General Thoracic and Cardiovascular Surgery | Issue 7/2016

Login to get access

Abstract

Multidisciplinary therapies have been developed to prolong the survival of patients with resectable esophageal cancer. Worldwide, neoadjuvant therapy has become the standard treatment for locally advanced resectable esophageal cancer. In this article, we briefly review the clinical trials and meta-analyses of neoadjuvant therapy for advanced esophageal cancer. In Europe and the USA, neoadjuvant chemoradiotherapy is regarded as the standard treatment, while neoadjuvant chemotherapy has become the standard treatment in Japan based on the results of clinical trials. Changes in treatment, according to the period and the results of up-to-date studies, are discussed. As neoadjuvant therapy is administered with the assumption that surgery will be performed, it is important for surgeons to be familiar with its impact on surgical management. We also review the impact of neoadjuvant therapy on surgical management. Issues such as the timing of surgery after neoadjuvant therapy, the extent of lymph node dissection, and the operative approach in relation to the esophagus are matters to be elucidated in the future.
Literature
1.
Cliffton EE, Goodner JT, Bronstein E. Preoperative irradiation for cancer of the esophagus. Cancer. 1960;13:37–45.CrossRefPubMed
2.
Shields TW, Rosen ST, Hellerstein SM, Tsang T, Ujiki GT, Kies MS. Multimodality approach to treatment of carcinoma of the esophagus. Arch Surg. 1984;119:558–62.CrossRefPubMed
3.
Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl):6:vi51–6.
4.
Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13:194–227.PubMed
5.
Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRefPubMed
6.
Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg. 1997;114:210–7.CrossRefPubMed
7.
Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979–84.CrossRefPubMed
8.
Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165–74.CrossRefPubMed
9.
Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727–33.CrossRef
10.
Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer. 2011;11:181.CrossRefPubMedPubMedCentral
11.
Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–7.CrossRefPubMed
12.
Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.CrossRefPubMed
13.
Kidane B, Coughlin S, Vogt K, Malthaner R. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 2015;5:CD001556.PubMed
14.
Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60:1449–72.CrossRefPubMed
15.
Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol. 2003;21:4592–6.CrossRefPubMed
16.
Hirao M, Ando N, Tsujinaka T, Udagawa H, Yano M, Yamana H, et al. Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg. 2011;98:1735–41.CrossRefPubMed
17.
Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.CrossRefPubMed
18.
Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.CrossRefPubMed
19.
Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161–7.CrossRefPubMed
20.
Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659–68.CrossRefPubMed
21.
Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–13.PubMed
22.
23.
Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004;53:925–30.CrossRefPubMedPubMedCentral
24.
Greer SE, Goodney PP, Sutton JE, Birkmeyer JD. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005;137:172–7.CrossRefPubMed
25.
Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.CrossRefPubMed
26.
Wijnhoven BP, van Lanschot JJ, Tilanus HW, Steyerberg EW, van der Gaast A. Neoadjuvant chemoradiotherapy for esophageal cancer: a review of meta-analyses. World J Surg. 2009;33:2606–14.CrossRefPubMedPubMedCentral
27.
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed
28.
Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.CrossRefPubMed
29.
30.
Zacherl J. The current evidence in support of multimodal treatment of locally advanced, potentially resectable esophageal cancer. Dig Dis. 2014;32:171–5.CrossRefPubMed
31.
Weber C. Oesophageal cancer: neoadjuvant chemoradiotherapy and surgery superior to surgery alone. Nat Rev Gastroenterol Hepatol. 2015;12:489.CrossRefPubMed
32.
Iizuka T, Ide H, Kakegawa T, Sasaki K, Takagi I, Ando N, et al. Preoperative radioactive therapy for esophageal carcinoma. Randomized evaluation trial in eight institutions. Chest. 1988;93:1054–8.CrossRefPubMed
33.
Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg. 1981;194:438–46.CrossRefPubMedPubMedCentral
34.
Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology. 1991;48:411–20.CrossRefPubMed
35.
Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43:752–5.CrossRefPubMed
36.
Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6.CrossRefPubMed
37.
Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47:354–60.CrossRefPubMed
38.
Klevebro F, Alexandersson von Dobeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. A randomised clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27:660–7.CrossRefPubMed
39.
Heidecke CD, Weighardt H, Feith M, Fink U, Zimmermann F, Stein HJ, et al. Neoadjuvant treatment of esophageal cancer: immunosuppression following combined radiochemotherapy. Surgery. 2002;132:495–501.CrossRefPubMed
40.
Westerterp M, Boermeester MA, Omloo JM, Hulshof MC, Vervenne WL, Lutter R, et al. Differential responses of cellular immunity in patients undergoing neoadjuvant therapy followed by surgery for carcinoma of the oesophagus. Cancer Immunol Immunother. 2008;57:1837–47.CrossRefPubMed
41.
Tsutsui S, Morita M, Kuwano H, Matsuda H, Mori M, Okamura S, et al. Influence of preoperative treatment and surgical operation on immune function of patients with esophageal carcinoma. J Surg Oncol. 1992;49:176–81.CrossRefPubMed
42.
Ling Y, Fan L, Dong C, Zhu J, Liu Y, Ni Y, et al. Combined influence of adjuvant therapy and interval after surgery on peripheral CD4(+) T lymphocytes in patients with esophageal squamous cell carcinoma. Exp Ther Med. 2010;1:113–20.PubMedPubMedCentral
43.
Werner-Wasik M, Yu X, Marks LB, Schultheiss TE. Normal-tissue toxicities of thoracic radiation therapy: esophagus, lung, and spinal cord as organs at risk. Hematol Oncol Clin North Am. 2004;18:131–60.CrossRefPubMed
44.
El-Malt M, Ceelen W, van den Broecke C, Cuvelier C, Van Belle S, De Neve W, et al. Healing of experimental colonic anastomoses: effects of combined preoperative high-dose radiotherapy and intraperitoneal 5-fluorouracil. Int J Cancer. 2001;96:297–304.CrossRefPubMed
45.
Kuzu MA, Koksoy C, Akyol FH, Uzal D, Kale IT. Colonic anastomotic healing after preoperative chemo-radiotherapy in rat. Radiat Med. 1999;17:181–7.PubMed
46.
Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37:300–11.CrossRefPubMed
47.
Tripp P, Malhotra HK, Javle M, Shaukat A, Russo R, De Boer S, et al. Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes. Dis Esophagus. 2005;18:400–5.CrossRefPubMed
48.
Lund M, Alexandersson von Dobeln G, Nilsson M, Winter R, Lundell L, Tsai JA, et al. Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction—a prospective cohort pilot study within a randomized clinical trial. Radiat Oncol. 2015;10:16.CrossRefPubMedPubMedCentral
49.
Liedman B, Johnsson E, Merke C, Ruth M, Lundell L. Preoperative adjuvant radiochemotherapy may increase the risk in patients undergoing thoracoabdominal esophageal resections. Dig Surg. 2001;18:169–75.CrossRefPubMed
50.
Kountourakis P, Correa AM, Hofstetter WL, Lee JH, Bhutani MS, Rice DC, et al. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011;117:925–30.CrossRefPubMed
51.
Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014;32:2416–22.CrossRefPubMed
52.
Czito BG, Palta M, Willett CG. Results of the FFCD 9901 trial in early-stage esophageal carcinoma: is it really about neoadjuvant therapy? J Clin Oncol. 2014;32:2398–400.CrossRefPubMed
53.
Ruol A, Portale G, Castoro C, Merigliano S, Cagol M, Cavallin F, et al. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer. Ann Surg Oncol. 2007;14:3243–50.CrossRefPubMed
54.
Fogh SE, Yu A, Kubicek GJ, Scott W, Mitchell E, Rosato EL, et al. Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy? Int J Radiat Oncol Biol Phys. 2011;80:1372–6.CrossRefPubMed
55.
Puts MT, Santos B, Hardt J, Monette J, Girre V, Atenafu EG, et al. An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol. 2014;25:307–15.CrossRefPubMed
56.
Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BP, Biermann K, ten Kate FJ, et al. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg. 2014;260:807–13.CrossRefPubMed
57.
Tessier W, Gronnier C, Messager M, Hec F, Mirabel X, Robb WB, et al. Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer? Ann Thorac Surg. 2014;97:1181–9.CrossRefPubMed
58.
Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, et al. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg. 2015;99:270–6.CrossRefPubMed
59.
Ruol A, Rizzetto C, Castoro C, Cagol M, Alfieri R, Zanchettin G, et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome? Ann Surg. 2010;252:788–96.CrossRefPubMed
60.
Chiu CH, Chao YK, Chang HK, Tseng CK, Chan SC, Liu YH, et al. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? Ann Surg Oncol. 2013;20:4245–51.CrossRefPubMed
61.
Lin G, Han SY, Xu YP, Mao WM. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies. Dis Esophagus. 2015. doi:10.​1111/​dote.​12432.
62.
Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg. 2001;72:1918–24.CrossRefPubMed
63.
Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 2004;240:962–72.CrossRefPubMedPubMedCentral
64.
Altorki NK, Zhou XK, Stiles B, Port JL, Paul S, Lee PC, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221–6.CrossRefPubMed
65.
Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549–56.CrossRefPubMed
66.
Rizk NP, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251:46–50.CrossRefPubMed
67.
Stiles BM, Nasar A, Mirza FA, Lee PC, Paul S, Port JL, et al. Worldwide Oesophageal Cancer Collaboration guidelines for lymphadenectomy predict survival following neoadjuvant therapy. Eur J Cardiothorac Surg. 2012;42:659–64.CrossRefPubMed
68.
Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.CrossRefPubMed
69.
Torgersen Z, Sundaram A, Hoshino M, Willer B, Fang X, Tashi T, et al. Prognostic implications of lymphadenectomy in esophageal cancer after neo-adjuvant therapy: a single center experience. J Gastrointest Surg. 2011;15:1769–76.CrossRefPubMed
70.
Solomon N, Zhuge Y, Cheung M, Franceschi D, Koniaris LG. The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma. Ann Surg Oncol. 2010;17:791–803.CrossRefPubMed
71.
Koen Talsma A, Shapiro J, Looman CW, van Hagen P, Steyerberg EW, van der Gaast A, et al. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg. 2014;260:786–92.CrossRefPubMed
72.
Robb WB, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, et al. Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial. Ann Surg. 2015;261:902–8.CrossRefPubMed
73.
Vallbohmer D, Holscher AH, DeMeester S, DeMeester T, Salo J, Peters J, et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010;252:744–9.CrossRefPubMed
74.
Shridhar R, Hoffe SE, Almhanna K, Weber JM, Chuong MD, Karl RC, et al. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2013;20:3038–43.CrossRefPubMed
75.
Boshier PR, Anderson O, Hanna GB. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. Ann Surg. 2011;254:894–906.CrossRefPubMed
76.
Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–9.CrossRefPubMed
77.
Talsma K, Wijnhoven B, van Lanschot J, van Berge Henegouwen M. Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial. Ann Surg. 2015. doi:10.​1097/​SLA.​0000000000001358​.
78.
Rizzetto C, DeMeester SR, Hagen JA, Peyre CG, Lipham JC, DeMeester TR. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2008;135:1228–36.CrossRefPubMed
79.
Morgan MA, Lewis WG, Hopper AN, Escofet X, Havard TJ, Brewster AE, et al. Prospective comparison of transthoracic versus transhiatal esophagectomy following neoadjuvant therapy for esophageal cancer. Dis Esophagus. 2007;20:225–31.CrossRefPubMed
80.
81.
Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379:1887–92.CrossRefPubMed
82.
Maas KW, Cuesta MA, van Berge Henegouwen MI, Roig J, Bonavina L, Rosman C, et al. Quality of life and late complications after minimally invasive compared to open esophagectomy: results of a randomized trial. World J Surg. 2015;39:1986–93.CrossRefPubMedPubMedCentral
83.
Ben-David K, Rossidis G, Zlotecki RA, Grobmyer SR, Cendan JC, Sarosi GA, et al. Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy. Ann Surg Oncol. 2011;18:3324–9.CrossRefPubMed
84.
Thomay AA, Snyder JA, Edmondson DM, Scott WJ. Initial results of minimally invasive Ivor Lewis esophagectomy after induction chemoradiation (50.4 gy) for esophageal cancer. Innovations (Phila). 2012;7:421–8.
85.
Warner S, Chang YH, Paripati H, Ross H, Ashman J, Harold K, et al. Outcomes of minimally invasive esophagectomy in esophageal cancer after neoadjuvant chemoradiotherapy. Ann Thorac Surg. 2014;97:439–45.CrossRefPubMed
86.
Spector R, Zheng Y, Yeap BY, Wee JO, Lebenthal A, Swanson SJ, et al. The 3-hole minimally invasive esophagectomy: a safe procedure following neoadjuvant chemotherapy and radiation. Semin Thorac Cardiovasc Surg. 2015;27:205–15.CrossRefPubMed
87.
Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg. 2010;97:1482–96.CrossRefPubMed
88.
Merritt RE, Whyte RI, D’Arcy NT, Hoang CD, Shrager JB. Morbidity and mortality after esophagectomy following neoadjuvant chemoradiation. Ann Thorac Surg. 2011;92:2034–40.CrossRefPubMed
89.
Morita M, Masuda T, Okada S, Yoshinaga K, Saeki H, Tokunaga E, et al. Preoperative chemoradiotherapy for esophageal cancer: factors associated with clinical response and postoperative complications. Anticancer Res. 2009;29:2555–62.PubMed
90.
Reynolds JV, Ravi N, Hollywood D, Kennedy MJ, Rowley S, Ryan A, et al. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J Thorac Cardiovasc Surg. 2006;132:549–55.CrossRefPubMed
91.
Bosch DJ, Muijs CT, Mul VE, Beukema JC, Hospers GA, Burgerhof JG, et al. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients. Ann Surg Oncol. 2014;21:605–11.CrossRefPubMed
92.
Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013;86:885–91.CrossRefPubMedPubMedCentral
93.
Kumagai K, Rouvelas I, Tsai JA, Mariosa D, Klevebro F, Lindblad M, et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg. 2014;101:321–38.CrossRefPubMed
94.
Escofet X, Manjunath A, Twine C, Havard TJ, Clark GW, Lewis WG. Prevalence and outcome of esophagogastric anastomotic leak after esophagectomy in a UK regional cancer network. Dis Esophagus. 2010;23:112–6.CrossRefPubMed
95.
Walle CV, Ceelen WP, Boterberg T, Putte DV, Van Nieuwenhove Y, Varin O, et al. Anastomotic complications after Ivor Lewis esophagectomy in patients treated with neoadjuvant chemoradiation are related to radiation dose to the gastric fundus. Int J Radiat Oncol Biol Phys. 2012;82:e513–9.CrossRef
96.
Juloori A, Tucker SL, Komaki R, Liao Z, Correa AM, Swisher SG, et al. Influence of preoperative radiation field on postoperative leak rates in esophageal cancer patients after trimodality therapy. J Thorac Oncol. 2014;9:534–40.CrossRefPubMedPubMedCentral
97.
Koeter M, van der Sangen MJ, Hurkmans CW, Luyer MD, Rutten HJ, Nieuwenhuijzen GA. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy. Radiat Oncol. 2015;10:59.CrossRefPubMedPubMedCentral
98.
Gronnier C, Trechot B, Duhamel A, Mabrut JY, Bail JP, Carrere N, et al. Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study. Ann Surg. 2014;260:764–70.CrossRefPubMed
Metadata
Title
Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management
Authors
Masahiko Ikebe
Masaru Morita
Manabu Yamamoto
Yasushi Toh
Publication date
01-07-2016
Publisher
Springer Japan
Published in
General Thoracic and Cardiovascular Surgery / Issue 7/2016
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-016-0655-y

Other articles of this Issue 7/2016

General Thoracic and Cardiovascular Surgery 7/2016 Go to the issue

Original Article

Experimental validation of talc pleurodesis for carcinomatous pleuritis in an animal model

Case Report

Total pleural covering technique for intractable pneumothorax in patient with Ehlers–Danlos syndrome

Case Report

Superior mesenteric artery plasty for type A acute aortic dissection with visceral ischemia

Case Report

Successful surgical treatment for total circumferential aortic and mitral annulus calcification: application of half-and-half technique

Current Topics Review Article

Postoperative residua and sequelae in adults with repaired tetralogy of Fallot

Original Article

Long-term outcomes of tear-oriented ascending/hemiarch replacements for acute type A aortic dissection